Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044915 · ClinicalTrials.gov registry record · Phase 2
Repinotan in Patients With Acute Ischemic Stroke
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 782
- Enrollment target
NCT00044915 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 782 participants.
The verdict
NCT00044915, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 782 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate Repinotan HCl in patients with acute ischemic stroke. At study entry patients will be randomized to Repinotan HCl or placebo in a 1:1 ratio. The total treatment period wil be 72 hours.
Interventions
- DRUG Placebo
- DRUG Repinotan HCl (BAYX3702)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 782 participants |
| Start Date | 2000-12 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044915
The ClinicalTrials.gov registry entry for NCT00044915 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 782 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00044915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00044915 about?
NCT00044915 is a clinical study titled "Repinotan in Patients With Acute Ischemic Stroke". The purpose of this trial is to evaluate Repinotan HCl in patients with acute ischemic stroke. At study entry patients will be randomized to Repinotan HCl or placebo in a 1:1 ratio. The total treatment period wil be 72 hours.
What is the current status of trial NCT00044915?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 782 participants. The study started on 2000-12. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00044915?
The interventions under investigation include: Placebo (DRUG), Repinotan HCl (BAYX3702) (DRUG).
Who is sponsoring clinical trial NCT00044915?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.